BEHRENS M KATHLEEN 4

What Happened

• Kathleen M. Behrens, a director of Sarepta Therapeutics (SRPT), exercised stock options on 2026-01-27 to acquire 10,500 shares. The exercise reflects a total cash value of approximately $143,955 (10,500 shares × $13.71).
• To satisfy the exercise price/tax withholding, the issuer withheld 6,494 of the shares (reported as a disposition) valued at about $143,972 (6,494 shares × $22.17). After withholding, Behrens received and holds the remaining 4,006 shares.

Key Details

• Transaction date: 2026-01-27; Form 4 filed 2026-01-29 (timely filing).
• Primary actions reported: M = option exercise (10,500 shares acquired); F = shares withheld to pay exercise price/taxes (6,494 shares disposed).
• Prices/values: exercised 10,500 shares @ $13.71 = $143,955; 6,494 shares withheld @ $22.17 = $143,972.
• Net shares received: 4,006 shares retained by the reporting person (10,500 − 6,494).
• Footnote: Issuer withheld shares to satisfy the option exercise price; the reporting person holds the exercised shares not withheld.

Context

• This was an option exercise with a net-share/cashless-like settlement (issuer withheld shares to cover exercise/taxes). That means part of the position was converted to cover costs rather than an outright market sale.
• Option exercises are common insider transactions and are not direct buy/sell signals; the filing is informational about changes in insider holdings.